🇺🇸 FDA
Patent

US 10106616

Antagonist antibodies to human prolactin receptor (PRLR)

granted A61KA61K2039/505A61K31/537

Quick answer

US patent 10106616 (Antagonist antibodies to human prolactin receptor (PRLR)) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K31/537, A61K47/68031, A61K47/68033